Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05188313
Title TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer (TRAP-2)
Acronym TRAP-2
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Age Groups: adult | senior
Covered Countries NLD

No variant requirements are available.